WO2024251826 - GLYCO-ENGINEERED ANTIBODY-DRUG-CONJUGATES COMPRISING AN OXIME LINKER
National phase entry is expected:
Publication Number
WO/2024/251826
Publication Date
12.12.2024
International Application No.
PCT/EP2024/065484
International Filing Date
05.06.2024
Title **
[English]
GLYCO-ENGINEERED ANTIBODY-DRUG-CONJUGATES COMPRISING AN OXIME LINKER
[French]
CONJUGUÉS ANTICORPS-MÉDICAMENT MODIFIÉS PAR GLYCO COMPRENANT UN LIEUR OXIME
Applicants **
VIB VZW
Suzanne Tassierstraat 1
9052 Gent, BE
UNIVERSITEIT GENT
Sint-Pietersnieuwstraat 25
9000 Gent, BE
Inventors
CALLEWAERT, Nico
c/o VIB-UGent Center for Medical Biotechnology
Technologiepark-Zwijnaarde 75
9052 Gent, BE
VAN MOER, Berre
c/o VIB-UGent Center for Medical Biotechnology
Technologiepark-Zwijnaarde 75
9052 Gent, BE
Priority Data
23177422.5
05.06.2023
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1435 | |
| EPO | Filing, Examination | 5653 | |
| Japan | Filing | 530 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 3835 |
Total: 12028 USD
Abstract[English]
The present invention relates to the field of antibody-drug-conjugates (ADCs) and the application of glyco-engineering strategies in a novel site-specific conjugation technology. The invention particularly relates to ADCs wherein a drug entity is conjugated an aminooxy-functionalized linker at di- or trisaccharide N-glycans in the hinge region, and methods for producing the same. More particularly, said conjugate is obtained through oxidized galactose- or sialyl-groups obtained from glyco-engineered eukaryotic cells which produce antibodies with an N-glycan structure that is limited to a shortened Asn- GlcNac-Gal(-Sia) branch in the hinge region of the antibody.[French]
La présente invention concerne le domaine des conjugués anticorps-médicament (ADC, « antibody-drug conjugate ») et l'application de stratégies de glyco-ingénierie dans une nouvelle technologie de conjugaison spécifique à un site. L'invention concerne en particulier des ADC dans lesquels une entité de médicament est conjuguée à un lieur fonctionnalisé par un aminooxy au niveau de N-glycanes de di-ou trisaccharide dans la région de charnière, ainsi que des procédés de production de ceux-ci. Plus particulièrement, ledit conjugué est obtenu par l'intermédiaire de groupes galactose ou sialyl oxydés obtenus à partir de cellules eucaryotes glyco-modifiées qui produisent des anticorps ayant une structure N-glycane qui est limitée à une branche Asn-GlcNac-Gal(-Sia) raccourcie dans la région charnière de l'anticorps.